142 related articles for article (PubMed ID: 1277216)
1. Identification and pharmacokinetics of cyclophosphamide (NSC-26271) metabolites in vivo.
Voelcker G; Wagner T; Hohorst HJ
Cancer Treat Rep; 1976 Apr; 60(4):415-22. PubMed ID: 1277216
[TBL] [Abstract][Full Text] [Related]
2. Approaches to the pharmacokinetics of cyclophosphamide (NSC 26271): Quantitation of metabolites.
Jardine I; Brundrett R; Colvin M; Fenselau C
Cancer Treat Rep; 1976 Apr; 60(4):403-8. PubMed ID: 1277214
[TBL] [Abstract][Full Text] [Related]
3. Cyclophosphamide (NSC-26271)-related phosphoramide mustards- recent advances and historical perspective.
Friedman OM; Wodinsky I; Myles A
Cancer Treat Rep; 1976 Apr; 60(4):337-46. PubMed ID: 1277209
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacokinetics of cyclophosphamide and cyclophosphamide metabolites in the mouse and their influence on the therapeutic effect of "activated" cyclophosphamide (4-hydroxycyclophosphamide) (author's transl)].
Voelcker G; Haeglsperger R
Arzneimittelforschung; 1982; 32(6):639-47. PubMed ID: 7202370
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of 4-hydroxycyclophosphamide and metabolites in the rat.
Hong PS; Srigritsanapol A; Chan KK
Drug Metab Dispos; 1991; 19(1):1-7. PubMed ID: 1673381
[TBL] [Abstract][Full Text] [Related]
6. Deactivation of cyclophosphamide (NSC-26271) metabolites by sulfhydryl compounds.
Draeger J; Peter G; Hohorst HJ
Cancer Treat Rep; 1976 Apr; 60(4):355-9. PubMed ID: 1277211
[TBL] [Abstract][Full Text] [Related]
7. Comparative pharmacologic study in vitro and in vivo with cyclophosphamide (NSC-26271), cyclophosphamide metabolites, and plain nitrogen mustard compounds.
Brock N
Cancer Treat Rep; 1976 Apr; 60(4):301-8. PubMed ID: 1277205
[TBL] [Abstract][Full Text] [Related]
8. Half-life of oxazaphosphorines in biological fluids.
Sladek NE; Powers JF; Grage GM
Drug Metab Dispos; 1984; 12(5):553-9. PubMed ID: 6149904
[TBL] [Abstract][Full Text] [Related]
9. Characterization of cyclophosphamide (NSC-26271) metabolites and related derivatives by field-desorption and electron-impact mass spectrometry.
Przybylski M; Ringsdorf H; Voelcker G; Draeger U; Peter G; Hohorst HJ
Cancer Treat Rep; 1976 Apr; 60(4):509-16. PubMed ID: 1277228
[TBL] [Abstract][Full Text] [Related]
10. Studies on the selective action of cyclophosphamide (NSC-26271): Inactivation of the hydroxylated metabolite by tissue-soluble enzymes.
Cox PJ; Phillips BJ; Thomas P
Cancer Treat Rep; 1976 Apr; 60(4):321-6. PubMed ID: 179712
[TBL] [Abstract][Full Text] [Related]
11. The problem of oncostatic specificity of cyclophosphamide (NSC-26271): Studies on reactions that control the alkylating and cytotoxic activity.
Hohorst HJ; Draeger U; Peter G; Voelcker G
Cancer Treat Rep; 1976 Apr; 60(4):309-15. PubMed ID: 1277206
[TBL] [Abstract][Full Text] [Related]
12. Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite.
Struck RF; Kirk MC; Witt MH; Laster WR
Biomed Mass Spectrom; 1975 Feb; 2(1):46-52. PubMed ID: 1131393
[TBL] [Abstract][Full Text] [Related]
13. Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy.
Jardine I; Fenselau C; Appler M; Kan MN; Brundrett RB; Colvin M
Cancer Res; 1978 Feb; 38(2):408-15. PubMed ID: 620410
[TBL] [Abstract][Full Text] [Related]
14. Biologic activity of two derivatives and six possible metabolites of cyclophosphamide (NSC-26271).
Lelieveld P; van Putten LM
Cancer Treat Rep; 1976 Apr; 60(4):373-9. PubMed ID: 1064468
[TBL] [Abstract][Full Text] [Related]
15. The use of deuterated analogs in qualitative and quantitative investigations of the metabolism of cyclophosphamide (NSC-26271).
Cox PJ; Farmer PB; Foster AB; Gilby ED; Jarman M
Cancer Treat Rep; 1976 Apr; 60(4):483-91. PubMed ID: 1277225
[TBL] [Abstract][Full Text] [Related]
16. Permeation of cyclophosphamide (NSC-26271) metabolites into tumor cells.
Draeger U; Hohorst HJ
Cancer Treat Rep; 1976 Apr; 60(4):423-7. PubMed ID: 1277217
[TBL] [Abstract][Full Text] [Related]
17. Identification of aldophosphamide as a metabolite of cyclophosphamide in vitro and in vivo in humans.
Fenselau C; Kan MN; Rao SS; Myles A; Friedman OM; Colvin M
Cancer Res; 1977 Aug; 37(8 Pt 1):2538-43. PubMed ID: 872080
[TBL] [Abstract][Full Text] [Related]
18. Studies on 4-hydroperoxycyclophosphamide (NSC-181815): a simple preparation method and its application for the synthesis of a new class of "activated" sulfur-containing cyclophosphamide (NSC-26271) derivatives.
Peter G; Wagner T; Hohorst HJ
Cancer Treat Rep; 1976 Apr; 60(4):429-35. PubMed ID: 1277218
[TBL] [Abstract][Full Text] [Related]
19. Accelerated decomposition of 4-hydroxycyclophosphamide by human serum albumin.
Kwon CH; Maddison K; LoCastro L; Borch RF
Cancer Res; 1987 Mar; 47(6):1505-8. PubMed ID: 3815352
[TBL] [Abstract][Full Text] [Related]
20. Two stable Fenton oxidation products of cyclophosphamide (NSC-26271) as precursors of 4-hydroxycyclophosphamide (NSC-196562) under physiologic conditions.
Benckhuysen C; van der Steen J; Spanjersberg EJ
Cancer Treat Rep; 1976 Apr; 60(4):369-72. PubMed ID: 945125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
